Differences between revisions 12 and 42 (spanning 30 versions)
Revision 12 as of 2005-11-28 15:34:04
Size: 2206
Editor: mskresolve-b
Comment:
Revision 42 as of 2005-12-05 16:37:20
Size: 933
Editor: mskresolve-b
Comment:
Deletions are marked like this. Additions are marked like this.
Line 1: Line 1:
=== About this Document === [[TableOfContents([2])]]

= About this Document =
Line 5: Line 7:
RFC 2 is divided in two parts: RFC 2 is divided in three parts:
Line 7: Line 9:
  * Part I consists of Ethan's interviews with six Cytoscapers (Trey, Gary, Ben, Allan, Aditya, and Rowan). I had hoped to interview more people before the Cytoscape retreat, but unfortunately didn't have time to get to everybody. In Part I, I have done my best to paraphrase people's comments, and I have not indicidated who said what.
  * Part II consists of ideas which were culled from Ethan's interviews, and are now presented as concrete proposals to the larger group.
  * Part I consists of Ethan's interviews with six Cytoscapers (Trey, Gary, Ben, Allan, Aditya, and Rowan). I had hoped to interview more people before the Cytoscape retreat, but unfortunately didn't have time to get to everybody. In Part I, I have done my best to paraphrase people's comments, and I have not indicated who said what. The order of comments, e.g. Cytoscaper #1, #2, etc. is arbitrary.
  * Part II consists of ideas generated at the 2005 Cytoscape retreat.
  * Part III consists of final, concreate ideas, which are being proposed to the Cytoscape gro
up.
Line 10: Line 13:
=== Status === = Status =
Line 14: Line 17:
== Part I: The Interviews == = Part I: The Interviews =
Line 16: Line 19:
=== Q1: What do you feel about the quality of the 2.2 release? === ["/Part 1"]
Line 18: Line 21:
==== Cytosaper #1: ====

  * We pushed the release date out too much. We should have coordinated our efforts much earlier; we probably could have done something by August. We could have done a much better job if we had coordinated earlier on. I think this compromised the quality of the chosen feature set.
  * Next time, we need to decide the feature set straight away. Then, do design and implementation in the next 2-3 months, so that we can do a real six month release cycle.
  * Feature set was based on developer interests, not really based on user's feedback. We need a better mechanism to get more feedback from real users.

==== Cytoscaper #2: ====

  * I think we chose the right set of features. For example, we chose a set of features that go well together, e.g. the new attribute browse goes well with the {{{CytoPanel}}} API. Plus, the editor fits in. Metanodes could have been in there too, and that would have been nice.
  * Timeliness could have been better. Quality could have been better.
  * That said, there are always trade-offs. In the tradeoff between: {{{GraphObjAttributes}}} v. {{{CytoscapeData}}} v. {{{CyAttributes}}}, I think we made the right decision. If we have had put Cytoscape 2.2 out the door a month ago without {{{CyAttributes}}}, it would have been a lot buggier.

== Part II: The Recommendations ==
= Part II: The Recommendations =

TableOfContents([2])

About this Document

This is an official Request for Comment (RFC) for "improving the quality of the Cytoscape 2.3 release."

RFC 2 is divided in three parts:

  • Part I consists of Ethan's interviews with six Cytoscapers (Trey, Gary, Ben, Allan, Aditya, and Rowan). I had hoped to interview more people before the Cytoscape retreat, but unfortunately didn't have time to get to everybody. In Part I, I have done my best to paraphrase people's comments, and I have not indicated who said what. The order of comments, e.g. Cytoscaper #1, #2, etc. is arbitrary.
  • Part II consists of ideas generated at the 2005 Cytoscape retreat.
  • Part III consists of final, concreate ideas, which are being proposed to the Cytoscape group.

Status

This document is under construction.

Part I: The Interviews

["/Part 1"]

Part II: The Recommendations

Under Construction

RFC_2 (last edited 2009-02-12 01:04:11 by localhost)

Funding for Cytoscape is provided by a federal grant from the U.S. National Institute of General Medical Sciences (NIGMS) of the Na tional Institutes of Health (NIH) under award number GM070743-01. Corporate funding is provided through a contract from Unilever PLC.

MoinMoin Appliance - Powered by TurnKey Linux